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Abstract: Estimating patient survival has hitherto been the main focus
when treating metastatic bone disease (MBD) in the appendicular
skeleton. This has been done in an attempt to allocate the patient to
a surgical procedure that outlives them. No questions have been
addressed as to whether the extent of the surgery and thus the surgical
trauma reduces survival in this patient group.
We wanted to evaluate if perioperative parameters such as blood
loss, extent of bone resection, and duration of surgery were risk factors
for 30-day mortality in patients having surgery due to MBD in the
appendicular skeleton.
We retrospectively identified 270 consecutive patients who under-
went joint replacement surgery or intercalary spacing for skeletal
metastases in the appendicular skeleton from January 1, 2003 to
December 31, 2013. We collected intraoperative (duration of surgery,
extent of bone resection, and blood loss), demographic (age, gender,
American Society of Anesthesiologist score [ASA score], and Kar-, PhD, Thea Bech d, Bach. Med.,
tersen, MD, DMSc
All patients were included in the analysis. ASA score 3þ 4 (OR 4.16
[95% confidence interval, CI, 1.80–10.85], P¼ 0.002) and Karnofsky
performance status below 70 (OR 7.34 [95% CI 3.16–19.20],
P< 0.001) were associated with increased 30-day mortality in univari-
ate analysis. This did not change in multivariable analysis. No
parameters describing the extent of the surgical trauma were found
to be associated with 30-day mortality.
The 30-day mortality in patients undergoing surgery for MBD is
highly dependent on the general health status of the patients as measured
by the ASA score and the Karnofsky performance status. The extent of
surgery, measured as duration of surgery, blood loss, and degree of bone
resection were not associated with 30-day mortality.
(Medicine 95(15):e3354)
Abbreviations: 95% CI = 95% confidence interval, ASA score =
American Society of Anesthesiologist score, MBD = metastatic
bone disease, OR = odds ratio.
INTRODUCTION
I n the acute setting, patients with metastatic bone disease(MBD) in the appendicular skeleton often pose an extraordi-
nary perioperative challenge. This is mainly caused by the
comorbidity of patients with MBD compared with other types
of orthopedic patients. Recent work evaluating a large, diverse
orthopedic patient population identified MBD as a strong,
independent risk factor for in-hospital mortality.1 Furthermore,
a previous study showed an increased embolic shower in
patients treated with intramedullary fixation or joint replace-
ment surgery in MBD patients compared with patients suffering
from nonpathological fractures.2
It is well known that patient survival after surgical treat-
ment of pathologic fractures or painful bony lesions due to
MBD is relatively poor.3–7 As such, surgical procedures are
almost always considered palliative in nature, and the extent of
surgery and choice of implant should be adapted to expected
postoperative survival for the individual patient.8–10 For these
patients, postoperative survival is considered to depend on their
general health and functional status and not the surgical trauma,
as described in previous studies.11–13 However, these studies
did not consider the relative impact on mortality from various
pre and perioperative factors. Since the American Society of
Anesthesiologists (ASA) Physical Status classification sys-
tem,14–16 duration of surgery,16 and blood loss17–22 have been
associated with short-term survival in other settings such as
surgery of the spine and joint replacement surgery, we hypoth-
esize that these and similar perioperative variables could betients as well.
uate if perioperative parameters such as
one resection, and duration of surgery
www.md-journal.com | 1
TABLE 1. Patient Demographics
Number of patients 270
Female/male 110/160
Age at surgery, y; median, range 64 (21–90)
ASA group (n¼ 259)
Group 1 14
Group 2 121
Group 3 115
Group 4 9
Major bone resection (n¼ 273)
Yes/no 165/108
Duration of surgery, min (n¼ 264)
Median (range) 156.5 (60–494)
Blood loss, mL (n¼ 248)
Median (range) 937.5 (100–7000)
Karnofsky score (n¼ 266)
Mean (range) 70% (30–100%)
Patients 70% 170
Patients <70% 96
Fracture/impending (n¼ 270)
Fracture 198
Sørensen et alwere risk factors for 30-day mortality in patients having surgery
due to MBD in the appendicular skeleton.
METHODS
Study Population and Design
Impending 72
ASA ¼ American Society of Anesthesiologist.We retrospectively identified a consecutive cohort of 270
patients who underwent joint replacement surgery (n¼ 270) and
intercalary spacing (n¼ 3) for MBD at our facility, a tertiary
FIGURE 1. Examples of surgical implant used. (A) Proximal humeru
Implantcast GmbH, Buxtehude, Germany) with a reverse shoulder joi
prosthesis (Segmental System, Zimmer, Warsaw, IN, USA). (C) Dis
(Segmental System, Zimmer, Warsaw, IN, USA). (D) Resection of t
(Osteobridge, Merete Medical GmbH, Berlin, Germany).
2 | www.md-journal.comreferral center for orthopedic oncology, from 2003 to 2013
(Table 1). Three patients had 2 or 3 skeletal sites treated as a 1-
stage procedure. Joints replaced were the hip (n¼ 210), the knee
(n¼ 25), the shoulder (n¼ 29), or the elbow (n¼ 6), and inter-
calary spacers were inserted in the femur (n¼ 2) or the humerus
(n¼ 1). Examples of surgical implants used are shown in
Figure 1. The patients who underwent surgery in 2003 to
2008 have previously been described in Sørensen et al,6,23
and patient demographics of the complete study cohort are
shown in Table 1. All patients had adequate follow-up to
establish survival at 30 days postsurgery. In case of multiple
operations during the inclusion period, patients were included in
the study at the time of the first operation only.
Variables
We collected intraoperative variables including duration of
surgery, blood loss (counted from blood in the drains and weight
of the surgical laps), and the degree of bone resection. This was
chosen as parameters for describing the magnitude of the
surgical trauma. The degree of bone resection was classified
as major, if resection was done below the lesser trochanter at the
hip, above the femoral condyles at the knee, below the surgical
neck of the proximal humerus, or above the condyles of the
distal humerus. In addition, age, gender, ASA score24 from the
preoperative evaluation by the anesthesiologist, and data for
estimating the Karnofsky performance score25 were collected
from the patient files.
We grouped the parameters as follows: blood loss above or
below the median (938mL), duration of surgery above or below
the median (157min), ASA scores were pooled into 2 groups (1
þ 2 and 3 þ 4), and age as described by Bauer and Wedin26
(below/equal to or above 65 years of age). Karnofsky perform-
ance score25 was grouped as above/equal to or below 70%. This
Medicine  Volume 95, Number 15, April 2016grouping was selected because a Karnofsky score above/equal
to 70% equals patients able to care for themselves in daily
activities. Primary cancers were divided into 3 different
s resection and reconstruction with a tumor prosthesis (Mutars,
nt. (B) Proximal femur resection and reconstruction with a tumor
tal femur resection and reconstruction with a tumor prosthesis
he femoral shaft and reconstruction with an intercalary spacer
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Type of Primary Cancer Type
n
Slow growth
Breast 78
Lymphoma 13
Myeloma 25
Moderate growth
Kidney 34
Uterus 3
Prostate 27
Sarcoma 2
Fast growth
Malignant melanoma 5
Cervix 1
Lung 39
Head and neck 4
Hepatocellular 2
Gastro intestinal 2
Pheochromocytoma 2
Colorectal 3
Bladder 7
Mediastinal 2
Angiosarcoma 2
Cancer of unknown primary site 19
Medicine  Volume 95, Number 15, April 2016 Surgery for Extremity Bony Metastasis Is Safeprognostic groups as described by Sørensen et al23 (Table 2).
Two patients had surgery due an osteosarcoma metastasis (a
primary cancer that was not described by Sørensen et al23) and
they were grouped into the moderate growth group as proposed
by Forsberg et al.12
Follow-Up
The follow-up on survival was until death or a minimum of
30 days postoperatively; no patients were excluded or lost to
follow-up. Survival time data were collected from the Danish
Civil Register on August 1, 2015 giving a complete follow-up.27
Statistics
Kaplan–Meier survival analysis was used for calculation
of the 30-day overall survival presented with the 95% confi-
dence interval (95% CI). Logistic regression with dichotomized
variables was used, and a stepwise backward elimination multi-
variable logistic regression was used to identify independent
risk factors for mortality, expressed as odds ratio (OR) with the
95% CI. P values< 0.05 were considered statistically signifi-
cant. We used R28 for the statistical calculations.
Ethics
The study was approved by the Danish Data Protection
Agency and the Danish Health and Medicines Authority.
RESULTS
We found a 30-day overall survival of 88% (95% CI 84–
92) (Figure 2). Unadjusted univariate logistic regression
Categorized into groups depending on growth rate of primary cancer.
A modification of grouping proposed by Sørensen et al.23analyses showed a significant increased 30-day mortality with
ASA score 3 þ 4 (OR 4.16 [95% CI 1.80–10.85], P¼ 0.002)
and Karnofsky performance status below 70 (OR 7.34 [95% CI
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.3.16–19.20], P< 0.001; Table 3). We found no significant
association between age, gender, blood loss, duration of
surgery, primary cancer type, or major bony resection and
the 30-day mortality in the univariate analysis (Table 3).
Duration of surgery seemed to influence mortality in the uni-
variate analysis with an OR for prolonged duration of surgery
(over 157min) of 0.46 (95% CI 0.20–1.00); however, this was
not statistically significant (P¼ 0.057).
The multivariable regression analysis showed that only
high ASA score and low Karnofsky score was independent risk
factors for 30-day mortality with an OR for ASA score of 2.83
(95% CI 1.69–7.61), P¼ 0.027 and for Karnofsky score 5.70
(95% CI 2.39–15.18), P< 0.001, respectively (Table 3).
Further evaluation of the distribution of the duration of
surgery in relation to ASA score revealed that confounding of
low ASA score patients to prolonged surgery was present in this
study (Figure 3).
DISCUSSION
We know from the literature that in general some perio-
perative factors such as blood loss, duration of surgery, and
comorbidity poses a risk for increased mortality when perform-
ing spinal surgery or joint replacement surgery.14–22 However,
whether the extent of surgery in patients treated for MBD in the
appendicular skeleton poses a risk for early mortality remains
unknown. We identified a statistically significant association
between 30-day mortality and the general health status of the
patients expressed as the ASA score and the Karnofsky score,
but we failed to demonstrate an association with intraoperative
variables such as blood loss, major bone resection, and duration
of surgery. We therefore conclude that the extent of surgery
does not influence a patient’s risk of dying within the first 30
days after surgical treatment of MBD.
The present study has limitations. Although we aimed to
include patients exposed to both small and extended surgery by
including patients who had regular arthroplasties as well as
larger tumor-prostheses and intercalary spacers inserted, we did
not have any data from patients having their MBD treated with
FIGURE 2. Kaplan–Meier survival curves. Thirty-day overall sur-
vival with 95% confidence interval.less invasive methods such as intramedullary nailing or plating.
It is also possible that other intraoperative metrics not captured
by this study could add prognostic information in this patient
www.md-journal.com | 3
TABLE 3. Regression Analysis
Univariate Analysis Multivariable Analysis
Logistic Regression
Analysis (n¼ 248)
Odds Ratio
(95% CI) P Value
Odds Ratio
(95% CI) P Value Reference
Demographics
Age at operation 1.87 (0.89–4.00) 0.100 n/s n/s <66 y
Gender 0.87 (0.41–1.86) 0.712 n/s n/s Male
Karnofsky group 7.34 (3.16–19.20) <0.001

5.7 (2.39–15.18) <0.001
 70
ASA group 4.16 (1.80–10.85) 0.002

2.83 (1.69–7.61) 0.027

ASA group 1 þ 2
Surgery characteristics
Bone resection 0.72 (0.35–1.54) 0.399 n/s n/s No major bone resection
Duration of surgery 0.46 (0.20–1.00) 0.057 n/s n/s <157min (median)
Blood loss 1.09 (0.49–2.44) 0.838 n/s n/s >938 mL (median)
Clinical
Primary cancer
Moderate growth cancer 0.53 (0.14–1.58) 0.282 n/s n/s Slow growth
Fast growth cancer 2.04 (0.91–4.67) 0.084 n/s n/s Slow growth
ASA ¼ American Society of Anesthesiologist, CI ¼ confidence interval, n/s¼ not significant.
Sørensen et al Medicine  Volume 95, Number 15, April 2016population. However, the authors find this unlikely since we
attempted to capture the most objective and widely used
variables, by including, for example, ASA score, primary tumor
location, extent of bone resection, duration of surgery, and
blood loss; each of which has been shown to be prognostic
factors in other areas of orthopedic surgery.1,9,11,15,17–22,24,29–38
Of all variables collected, only ASA score and Karnofsky
score were independently associated with 30-day mortality in
the present study. Several studies have been published describ-
ing parameters that relates to peri or postoperative mortality in
patients having surgery due to other pathologies than MBD.
Only 1 study32 has investigated if any perioperative variables
were associated with early mortality after surgery due to MBD
in the proximal femur and acetabulum. Quinn and Drenga32
were not able to identify any association between early
mortality and blood loss, duration of surgery, ASA score, type
of implant, or extent of resection. However, they found a
marginally significant association between the presence of a
pathological fracture and early mortality with an OR 8.37 (95%
CI 0.96–73.30). ASA score has been verified as a predictor

Statistically significant.for early mortality in the literature, when performing
orthopedic procedures in the spine or joint replacement
surgery15,19,20,29,30,34,35 so it is plausible that the ASA score
FIGURE 3. Histogram showing the distribution of ASA groups in
patients with short and long surgery duration. This shows a
selection of low ASA score patients to long surgical time. ASA
¼ American Society of Anesthesiologist.
4 | www.md-journal.comis of great importance, also when performing surgery due to
MBD in the appendicular skeleton as shown in our study.
A study from the Institutional Joint Registry, Mayo Clinic,
included a historical cohort of 12,727 patients undergoing
surgery with total hip arthroplasty and 12,484 patients with
total knee replacement.31 They identified high ASA score
(groups 3–4) and high Deyo-Charlson comorbidity index to
be associated with increased 90-day mortality. Although this
study only included patients suffering from a nonmalignant
disease, we feel that similarities of the surgical procedures allow
this study to be compared with our study to support the evidence
that the general health status of the patient is the main risk factor
for postoperative mortality. Wolters et al29 found an association
between increasing ASA score and increased risk of periopera-
tive blood loss and duration of surgery, though these variables
were not found to be independent predictors for postoperative
mortality in our study.
Other studies have investigated if blood loss and duration
of surgery pose a risk for postoperative mortality15,33,38 and
there seems to be lacking evidence as to whether or not these
parameters are true predictors or just strongly related to the
ASA score as indicated in 2 previously published studies.17,18
The literature is contradictory when it comes to the relation
between blood transfusions and postoperative mortality.19,20,22
In our institution, the amount of blood loss is well documented
with weighing of surgical laps and measurement of drains.
Evidence of blood transfusions relation to postoperative
mortality seems very weak. This might be due to the fact that
using units of blood transfusion as exposure, 1 does not know
whether 1 measures the effect a low preoperative hemoglobin
level has on mortality, perioperative blood loss, or the true
systemic reactions to transfusion and the relations to peri and
postoperative morbidity as indicated by Glance et al.21 In
theory, tumors with known high blood supply (e.g., kidney
tumors) might pose a risk of peri and postoperative mortality
due to the risk of major bleeding. However, our study was not
powered to detect such a relation with only 16 patients having
kidney tumor as primary cancer (average bleeding 1712 mL;
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
range 250–7000 mL). With this in mind, the authors feel
confident that perioperative blood loss within nonextreme
bleeding situations does not pose a risk for increased post-
operative mortality in patients having surgery due to MBD in
the appendicular skeleton.
Prolonged surgery seemed, in the univariate analysis, to be
a protective factor against high 30-day mortality rate. However,
this is most likely to be the result of the bias introduced into the
study by the institutional treatment philosophy: to reserve an
extended surgical approach for those patients who are estimated
to have a long postoperative survival. By extension, this
indicates a propensity toward less invasive or palliative surgery
in patients with high ASA scores, further emphasizing the
importance of patient selection and survival estimates. We have
shown an inverse relationship between ASA groups and
duration of surgery, as shown in Figure 3, which supports
this theory.
We did not find that the type of primary tumor poses a risk
for 30-day mortality. Still, the authors expect that type of
primary cancer poses a risk for mortality on a longer timeline.
Our choice of 30-day mortality to measure early postoperative
mortality was based upon the literature15,19–21,38,39 but can be
debated. Lie et al36 propose the use of a 21-day postoperative
period for measuring early postoperative mortality and argue
that 60 to 90 days might be a wrong timeline. Timeline of 21- or
30-day did not make a difference in our study.
In conclusion, our findings showed that the surgical trauma
does not pose an increased risk for death within the first 30 days
postoperatively. Early mortality in patients undergoing joint
replacement and intercalary replacement surgery for MBD is
dependent on the general health status of the patients, as
measured by the ASA score and Karnofsky performance score.
The extent of surgery, measured as duration of surgery, blood
loss, and extent of bone resection are not associated with 30-day
mortality. We therefore advise that surgeons decide a surgical
approach upon residual life expectancy and choose an implant
that will outlive the patient, as opposed to fear that the extent of
surgery and the surgical trauma poses a risk of increased
mortality in this patient group. Nevertheless, further research
is necessary to determine whether intraoperative or other vari-
ables are associated with very short postoperative survival in
patients with MBD.
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